Zenotech rituximab
Rituximab biosimilar developed by Zenotech Laboratories. Reference product MabThera (Rituxan in the United States).
About Zenotech rituximab
Zenotech received its rituximab permission in India in February 2013, for B-cell lymphoma, one day after Intas. The two were the first rituximab permissions in the published Indian lists. Zenotech is a Hyderabad company that also makes ranibizumab.
Status by market
United States
Not listed by FDA.
European Union
Not listed by EMA.
United Kingdom
Not listed by MHRA.
Japan
Not listed by PMDA.
Canada
Not listed by HC.
India
Central Drugs Standard Control OrganisationApprovedUnited Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where Zenotech rituximab holds an approval, these are the other rituximab biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| CDSCO | 6 | Biocad (Biocad rituximab), Hetero (Hetero rituximab), Intas Pharmaceuticals (Intas rituximab), Reliance Life Sciences (Reliance Life Sciences rituximab), Virchow Biotech (Virchow Biotech rituximab), Zydus Lifesciences (Zydus rituximab) |
Same developer, other molecules
Other biosimilars in the Atlas developed by Zenotech Laboratories: Zenotech ranibizumab.
Chronology
- CDSCOFeb 2013CDSCO permission granted
Sources
S014CDSCO, permissions granted in Form 46 and 46A, to 2019 Primary (regulator)
Planning rituximab biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultant